Rhythm Pharmaceuticals Presents Data From Its Long-term Extension Study Of Setmelanotide Showing Sustained And Deepened BMI Reduction In Patients With Hypothalamic Obesity At One Year At ObesityWeek 2023
Portfolio Pulse from Benzinga Newsdesk
Rhythm Pharmaceuticals (NASDAQ:RYTM) has presented data from its long-term extension study of setmelanotide, showing sustained and deepened BMI reduction in patients with hypothalamic obesity at one year. The study showed a mean BMI reduction of 25.5% in patients with hypothalamic obesity, and three of 11 pediatric patients achieved normal weight at one year. The company also presented data showing clinically relevant weight reductions in patients with Bardet-Biedl syndrome and POMC or LEPR deficiency obesity.
October 17, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals' setmelanotide shows promising results in long-term study, potentially boosting the company's reputation and stock value.
The positive results from the long-term study of setmelanotide could increase investor confidence in Rhythm Pharmaceuticals, potentially leading to an increase in stock value. The company's focus on rare diseases could also attract interest from investors looking for unique investment opportunities in the biopharma sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100